Matthew Johnson
Professor of Psychiatry
Data updated
Research Footprint
Matthew Johnson appears in 67 tracked papers (2008–2026) and 1 clinical trial, most studied alongside Psilocybin, LSD and Ayahuasca, across Substance Use Disorders (SUD), Anxiety Disorders and Depressive Disorders.
Most-cited paper: Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer (2144 citations).
Frequent co-authors: Roland Griffiths, Albert Garcia-Romeu and Frederick Barrett.
Publication Landscape
How the 67 papers Blossom tracks for Matthew Johnson line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Matthew Johnson's publishing grown?
SourcedTracked papers by publication year; 5 earlier papers published before 2012. Click a year for the running total.
Don't read as total output: only the 67 of 67 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Matthew Johnson publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Matthew Johnson publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Matthew W. Johnson is an established researcher in human hallucinogen science whose work spans clinical trials, survey-based epidemiology and experimental psychopharmacology. He has co‑authored and led influential studies examining psilocybin‑assisted interventions for substance use disorders (notably tobacco smoking cessation), naturalistic and clinical outcomes following classic psychedelic use (including reductions in alcohol use, psychological distress and suicidality), and dose‑related human effects of non-classic compounds such as salvinorin A. Johnson has collaborated extensively with other prominent investigators in the field to characterise both therapeutic mechanisms and adverse or challenging reactions, and has contributed to safety guidance for human hallucinogen research.
Key Impact
A leading clinical researcher who has advanced evidence on the therapeutic potential and safety of classic psychedelics—particularly psilocybin—for addiction and mental health outcomes through clinical trials, survey research and methodological guidance.
Collaboration Network
44 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Matthew Johnson's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Matthew Johnson is associated with.
Johns Hopkins University
academicThe Centre for Psychedelic and Consciousness Research focuses on how psychedelics affect behavior, cognition, brain function, and biological health markers. They have been at the forefront of demonstrating the safety and efficacy of psychedelics for mental disorders, expanding their focus into psilocybin research across multiple mental health conditions, including smoking cessation, major depressive disorder, and cancer-related anxiety.
View stakeholder →Johns Hopkins Center for Psychedelic and Consciousness Research
Founding faculty
The Johns Hopkins Center for Psychedelic and Consciousness Research sits within the School of Medicine in Baltimore and is one of the most established programmes of its kind. It opened in 2019 with roughly 17 million dollars in private donations, and was founded under Roland Griffiths, whose earlier psilocybin work helped revive modern clinical study of these compounds. Frederick Barrett took over as director in 2023. The centre studies how classic psychedelics such as psilocybin affect brain function, cognition and mood, and runs trials in conditions including depression, tobacco dependence and anorexia. Its scientists combine clinical trials with neuroimaging and questionnaire measures of the psychedelic experience, and much of the field's shared vocabulary traces back to work done here.
View stakeholder →